Aintik Completes Tens of Millions of RMB Series A Funding to Advance High-End Ultrasound Technology

Recently, VCBeat learned that Eintik Technology (Shanghai) Co., Ltd. has completed tens of millions of yuan in Series A financing.This round of financing was led by Fortune Capital, a top-tier investment institution. The funds will be used for core technological innovation, product development, market expansion, and team expansion., to comprehensively enhance the company's competitive advantage.

Eintik Technology, established in 2013, has earned numerous recognitions, including “National High-Tech Enterprise,” “Tech Little Giant,” and “Specialized, Refined, Differential, and Innovative Enterprise,” by virtue of its excellence in technological R&D and innovative applications. The company has set up its R&D and production headquarters and a metrology laboratory in Shanghai; an instrument R&D center in Guangzhou; and a sensor R&D center along with a 5,000-square-meter medical-grade production base in Changsha. It has also established branches in Beijing, Dongguan, Wuhan, Chengdu, and Xi’an. The company is certified under the ISO 9001, ISO 14001, and ISO 45001 management systems.

Eintik specializes in full-matrix capture ultrasonic phased array instruments, ultrasonic array probes, medical ultrasound probes (including ICE, IVUS, EUS, RDN, etc.), and customized intelligent ultrasound systems.The company centers its technological expertise on the development of high-end Phased Array Ultrasonic Testing (PAUT) products, providing comprehensive solutions that include ultrasonic probes, ultrasonic interface cards, and complete ultrasonic inspection systems, thereby deeply empowering downstream customers in ultrasonic applications.

Leveraging its robust innovation capabilities, the company has filed over 100 patents and software copyrights, participated in the drafting of more than 20 national or industry standards, and undertaken multiple projects for the commercialization of high-tech achievements. The company has engaged in industry-academia-research collaboration and technology transfer initiatives with numerous universities and research institutions, including Beihang University, Shanghai Jiao Tong University, Nanchang Hangkong University, Huazhong University of Science and Technology, Hangzhou Dianzi University, Sichuan University, Beijing University of Technology, Dongguan University of Technology, and Changhai Hospital.

As an innovative enterprise, Eintik will focus on deepening and improving its existing products and technologies in the short term, while also expanding its technology and product portfolio horizontally. In the medium to long term, Eintik plans to expand into overseas markets based on its coverage of the domestic market, thereby broadening its commercial layout. We look forward to witnessing the breakthrough achievements that Eintik will attain in the future.

Fortune Capital is one of the most influential venture capital firms in China. With its outstanding performance, Fortune Capital has consistently ranked among the top in evaluations conducted by authoritative institutions such as the China Venture Capital and Private Equity Association (CVCA), Zero2IPO Group, CVSource, and Financing China. It has been listed among Zero2IPO’s “Top 50 Best Venture Capital Firms in China” for 23 consecutive years, ranking first in 2012 and 2015, and maintaining a position within the top three domestic venture capital firms over the past decade. Furthermore, in the evaluations of private equity fund managers investing insurance funds conducted by the Insurance Asset Management Association of China (IAMAC) in 2020, 2021, 2022, and 2023, Fortune Capital was rated as a Class A institution with high scores for four consecutive years.